Mode
Text Size
Log in / Sign up

PD-1 and PD-L1 inhibitors increase the risk of skin rash in cancer patientsImmunotherapy drugs increase rash risks for cancer patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that PD-1 and PD-L1 inhibitors increase rash risk, especially when used in combination with other agents.

The authors conducted a meta-analysis of clinical trials to evaluate the incidence of rashes across all grades in cancer patients receiving PD-1 or PD-L1 inhibitors. The study examined these agents both as monotherapies and in combination with chemotherapy or other types of immunosuppressants, comparing them against chemotherapy alone, placebo, or combinations lacking specific immunotherapy components.

The analysis found that both PD-1 and PD-L1 inhibitors were associated with an increased risk of developing rashes compared to control groups. This risk was notably more pronounced when these agents were administered in combination with other immunosuppressive antitumor drugs. The data suggests a consistent trend of increased skin toxicity across various treatment combinations involving immune checkpoint inhibitors.

While the analysis establishes a clear association between these medications and rash occurrence, specific limitations regarding absolute numbers or individual patient outcomes were not reported. Clinicians should consider these findings as an indicator of potentialer side effects when managing patients on immunotherapy regimens. Monitoring for skin reactions is advisable, particularly when combination therapies are employed.

For many people fighting cancer, immunotherapy has become a vital tool in treatment. These drugs work by helping the immune system recognize and attack cancer cells. However, because these treatments involve activating the immune system, they can sometimes cause side effects that affect the skin. Understanding these risks is essential for patients and their families as they navigate treatment plans.

Researchers looked at data from 95 different clinical trials to see how specific types of immunotherapy affected patients. They focused on two main types of drugs: PD-1 inhibitors and PD-L1 inhibitors. These are often used alone or combined with chemotherapy and other treatments that weaken the immune response against tumors. The goal was to determine if these medications were more likely to cause skin rashes compared to standard treatments like chemotherapy alone or a placebo.

The results showed a clear link between these immunotherapy drugs and an increased risk of developing rashes. Patients taking PD-1 inhibitors had a higher risk of rashes than those on standard treatment. The risk was even higher for those taking PD-L1 inhibitors. Most importantly, the data showed that the risk of skin issues jumped significantly when these drugs were combined with other types of treatments like chemotherapy or other immunosuppressants. In some specific combinations, the risk of a rash was several times higher than in standard treatments.

While the study confirms that these medications are linked to more frequent rashes, it is important to remember that this is an analysis of many trials rather than a single study on one group of people. The data shows an increased risk, but it does not give specific numbers for how many patients will develop a rash or how severe those rashes will be for any individual person. For patients right now, this means that while these drugs are effective against cancer, the possibility of skin irritation is a known part of the treatment. If you or a loved one are starting immunotherapy, it is important to talk to your medical team about what kind of skin side effects to watch for. This information helps doctors monitor your health more closely and manage any discomfort that may arise during your journey.

What this means for you:
Immunotherapy drugs can increase the risk of skin rashes, especially when combined with other treatments.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: This study was designed to assess the risk of programmed cell death-1 (PD-1) or programmed cell death ligand 1 (PD-L1) related rash in various situations. METHODS: Guided by Preferred Reporting Items for Systematic Reviews and Meta-Analyses, data on rash in clinical trials related to PD-1 or PD-L1 were collected to comprehensively evaluate its incidence risk in various situations. RESULTS: Ninety-five clinical trials, divided into 12 groups according to treatment regimens, were enrolled for the final comprehensive assessments and analyses. Compared with chemotherapy or placebo alone, both PD-1 and PD-L1 inhibitors increased the risk of developing rashes for all grades (odds ratio [OR] = 1.61, P = .0003; OR = 2.94, P < .00001). Whether used in combination with chemotherapy or other types of immunosuppressants, similar risk trends were observed (OR = 2.42, P < .00001; OR = 2.11, P = .0007; OR = 4.49, P < .00001; OR = 5.15, P = .0006; OR = 3.16, P = .0002). CONCLUSION: Both PD-1 and PD-L1 increased the risk of rash occurrence, especially when used in combination with other immunosuppressive antitumor drugs.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.